On December 15, 2011, Covidien plc (NYSE: COV) announced plans to separate into two independent publicly traded companies. The spin company will be a leading manufacturer of generic drugs in the US, including acetaminophen. The pharmaceuticals business accounts for about $2 billion of COV’s $11.6 billion in annual sales. The parent (‘New Covidien’), a diversified medical products and supplies company, was spun off from Tyco International (NYSE: TYC) in 2007 and is based in Dublin, Ireland. The company sells a wide variety of vascular, respiratory, operating room monitoring, and nursing care products. About 80% of the parent’s revenue (post-separation) is generated from medical device sales.
The spin-off is expected be conducted via a tax-free distribution to shareholders, to be completed in mid-2013. Capital and liability allocations are yet to be finalized. The spin-off will require regulatory approval, an effective Form 10 filing with the SEC, an affirmative IRS ruling, and final approval from the board of directors. The spin company, which will assume the name ‘Mallinckrodt,’ intends to list on the NYSE under the symbol ‘MNK’.
As reasons for the separation, COV management cites differing business models, sales channels, customer profiles, and regulatory approval processes for the two businesses. The pharmaceuticals business may be able to focus more closely on its product pipeline and international expansion following the transaction.
The transaction is the latest from Covidien, which in recent years has transformed itself into a more focused medical devices company through acquisitions and divestitures. In doing so, the company was attempting to unlock value, given that medical devices companies trade at a premium to generic drug manufacturers. The pharmaceuticals business may have been a drag on the company’s valuation, as such the parent company may in fact experience a reduction in the costs of capital following the transaction.
The separation of the pharmaceuticals business will increase post-spin Covidien’s gross margins; R&D expense will become a smaller percentage of sales, while cash flow is expected to remain strong. New Covidien should be able to capitalize on industry growth trends for the foreseeable future, given a continued rollout of new products, expansion into international markets, and achieving deeper penetration in existing emerging markets. A fair value estimate of $56.98 per share for New Covidien can be derived.
Investors with a longer investment time horizon may see acceptable returns in New Covidien, given that the company will generate significant free cash flow, of which management intends to return 50% to shareholders through share repurchases and dividends.
Mallinckrodt appears to be focusing on developing an increasing number of branded pharmaceuticals to foster faster growth and higher margins. Vertically integrated manufacturing in both generics and nuclear imaging provide a favorable cost structure, which may make Mallinckrodt a takeout target. A fair value estimate of $6.71 per share for Mallinckrodt can be derived. On a sum-of-the-parts basis, a $63.69 fair value estimate can be derived. Given COV shares currently trade above this fair value, shares are not recommended for purchase prior to the spin-off transaction.